Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1

Blood Adv (2021) 5 (16): 3203–3215.

https://doi.org/10.1182/bloodadvances.2021004976

Published: 2021

Includes: Supplemental data

Journal Articles

A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDS

Blood Adv (2021) 5 (16): 3066–3075.

https://doi.org/10.1182/bloodadvances.2020004055

Published: 2021

Journal Articles

Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes

Grace A. Ward, Kathy L. McGraw, Farnoosh Abbas-Aghababazadeh, Benjamin S. Meyer, Amy F. McLemore, Nicole D. Vincelette, Nghi B. Lam, Amy L. Aldrich, Najla H. Al Ali, Eric Padron, Javier Pinilla-Ibarz, Erico Masala, Valeria Santini, Olivier Kosmider, Michaela Fontenay, Pierre Fenaux, Joseph Johnson, Brooke L. Fridley, Alan F. List

Blood Adv (2021) 5 (8): 2216–2228.

https://doi.org/10.1182/bloodadvances.2020003475

Published: 2021

Includes: Supplemental data

Journal Articles

Comorbidities and malignancies negatively affect survival in myelodysplastic syndromes: a population-based study

Johanne Rozema, Mels Hoogendoorn, Robby Kibbelaar, Eva van den Berg, Nic Veeger, Eric van Roon

Blood Adv (2021) 5 (5): 1344–1351.

https://doi.org/10.1182/bloodadvances.2020003381

Published: 2021

Includes: Supplemental data

Journal Articles

Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes

Anthony M. Hunter, Rami S. Komrokji, Seongseok Yun, Najla Al Ali, Onyee Chan, Jinming Song, Mohammad Hussaini, Chetasi Talati, Kendra L. Sweet, Jeffrey E. Lancet, Eric Padron, Alan F. List, David A. Sallman

Blood Adv (2021) 5 (4): 1017–1028.

https://doi.org/10.1182/bloodadvances.2020003508

Published: 2021

Includes: Supplemental data

Journal Articles

Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors

Blood Adv (2021) 5 (4): 975–983.

https://doi.org/10.1182/bloodadvances.2020003654

Published: 2021

Journal Articles

Guideline-based indicators for adult patients with myelodysplastic syndromes

Blood Adv (2020) 4 (16): 4029–4044.

https://doi.org/10.1182/bloodadvances.2020002314

Published: 2020

Includes: Supplemental data

Journal Articles

Treosulfan-based conditioning is feasible and effective for cord blood recipients: a phase 2 multicenter study

Filippo Milano, Jonathan A. Gutman, H. Joachim Deeg, Eneida R. Nemecek, Joachim Baumgart, Laurel Thur, Ann Dahlberg, Rachel B. Salit, Corinne Summers, Frederick R. Appelbaum, Colleen Delaney

Blood Adv (2020) 4 (14): 3302–3310.

https://doi.org/10.1182/bloodadvances.2020002222

Published: 2020

Includes: Supplemental data

Journal Articles

Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease

Matthew M. Hsieh, Melissa Bonner, Francis John Pierciey, Jr, Naoya Uchida, James Rottman, Laura Demopoulos, Manfred Schmidt, Julie Kanter, Mark C. Walters, Alexis A. Thompson, Mohammed Asmal, John F. Tisdale

Blood Adv (2020) 4 (9): 2058–2063.

https://doi.org/10.1182/bloodadvances.2019001330

Published: 2020

Journal Articles

Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome

Je-Hwan Lee, Stefan Faderl, John M. Pagel, Chul Won Jung, Sung-Soo Yoon, Animesh D. Pardanani, Pamela S. Becker, Howard Lee, Jeongeun Choi, Kyoungjune Lee, Minkyoung Kim, Jorge E. Cortes

Blood Adv (2020) 4 (9): 2032–2043.

https://doi.org/10.1182/bloodadvances.2019000757

Published: 2020

Includes: Supplemental data

Journal Articles

Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results

Blood Adv (2020) 4 (9): 1942–1949.

https://doi.org/10.1182/bloodadvances.2019001349

Published: 2020

Includes: Supplemental data

Journal Articles

A 4-gene leukemic stem cell score can independently predict the prognosis of myelodysplastic syndrome patients

Yu-Hung Wang, Chien-Chin Lin, Chi-Yuan Yao, Chia-Lang Hsu, Hsin-An Hou, Cheng-Hong Tsai, Wen-Chien Chou, Hwei-Fang Tien

Blood Adv (2020) 4 (4): 644–654.

https://doi.org/10.1182/bloodadvances.2019001185

Published: 2020

Includes: Supplemental data

Journal Articles

Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome

Frances Linzee Mabrey, Kelda M. Gardner, Kathleen Shannon Dorcy, Andrea Perdue, Heather A. Smith, Alicyn M. Davis, Cody Hammer, Donelle Rizzuto, Sunny Jones, Kim Quach, Bart L. Scott, Paul C. Hendrie, Mary-Elizabeth M. Percival, Roland B. Walter, Frederick R. Appelbaum, Elihu H. Estey, Pamela S. Becker

Blood Adv (2020) 4 (4): 611–616.

https://doi.org/10.1182/bloodadvances.2019000707

Published: 2020

Includes: Supplemental data

Journal Articles

A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia

Kirk E. Cahill, Yasmin H. Karimi, Theodore G. Karrison, Nitin Jain, Margaret Green, Howard Weiner, Noreen Fulton, Sabah Kadri, Lucy A. Godley, Andrew S. Artz, Hongtao Liu, Michael J. Thirman, Michelle M. Le Beau, Megan E. McNerney, Jeremy Segal, Richard A. Larson, Wendy Stock, Olatoyosi Odenike

Blood Adv (2020) 4 (4): 599–606.

https://doi.org/10.1182/bloodadvances.2019000795

Published: 2020

Includes: Supplemental data

Journal Articles

Genomic context and TP53 allele frequency define clinical outcomes in TP53 -mutated myelodysplastic syndromes

Blood Adv (2020) 4 (3): 482–495.

https://doi.org/10.1182/bloodadvances.2019001101

Published: 2020

Includes: Supplemental data

Journal Articles

Highly multiplexed proteomic assessment of human bone marrow in acute myeloid leukemia

Blood Adv (2020) 4 (2): 367–379.

https://doi.org/10.1182/bloodadvances.2019001124

Published: 2020

Includes: Supplemental data

Journal Articles

Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma

Armando Santoro, Rita Mazza, Alessandro Pulsoni, Alessandro Re, Maurizio Bonfichi, Vittorio Ruggero Zilioli, Manuela Zanni, Francesco Merli, Antonella Anastasia, Stefano Luminari, Giorgia Annechini, Manuel Gotti, Annalisa Peli, Anna Marina Liberati, Nicola Di Renzo, Luca Castagna, Laura Giordano, Francesca Ricci, Carmelo Carlo-Stella

Blood Adv (2020) 4 (1): 136–140.

https://doi.org/10.1182/bloodadvances.2019000984

Published: 2020

Includes: Supplemental data

Journal Articles

Bone marrow oxidative stress and specific antioxidant signatures in myelodysplastic syndromes

Frederic Picou, Christine Vignon, Christelle Debeissat, Sébastien Lachot, Olivier Kosmider, Nathalie Gallay, Amelie Foucault, Marie-Hélène Estienne, Noémie Ravalet, Marie C. Bene, Jorge Domenech, Emmanuel Gyan, Michaela Fontenay, Olivier Herault

Blood Adv (2019) 3 (24): 4271–4279.

https://doi.org/10.1182/bloodadvances.2019000677

Published: 2019

Includes: Supplemental data

Journal Articles

Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias

Blood Adv (2019) 3 (23): 3962–3967.

https://doi.org/10.1182/bloodadvances.2019000731

Published: 2019

Includes: Supplemental data

Journal Articles

Non-del(5q) myelodysplastic syndromes–associated loci detected by SNP-array genome-wide association meta-analysis

Blood Adv (2019) 3 (22): 3579–3589.

https://doi.org/10.1182/bloodadvances.2019000922

Published: 2019

Includes: Supplemental data

NARROW

Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1

A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDS

Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes

Comorbidities and malignancies negatively affect survival in myelodysplastic syndromes: a population-based study

Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes

Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors

Guideline-based indicators for adult patients with myelodysplastic syndromes

Treosulfan-based conditioning is feasible and effective for cord blood recipients: a phase 2 multicenter study

Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease

Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome

Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results

A 4-gene leukemic stem cell score can independently predict the prognosis of myelodysplastic syndrome patients

Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome

A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia

Genomic context and TP53 allele frequency define clinical outcomes in TP53 -mutated myelodysplastic syndromes

Highly multiplexed proteomic assessment of human bone marrow in acute myeloid leukemia

Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma

Bone marrow oxidative stress and specific antioxidant signatures in myelodysplastic syndromes

Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias

Non-del(5q) myelodysplastic syndromes–associated loci detected by SNP-array genome-wide association meta-analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only